Treating dry age-related macular degeneration: 6 things to know

What an eye specialist says about new medications for dry AMD

12:19 PM

Author | Tessa Roy

eyes close up green blue
Getty Images

Do you have questions about treatment of age-related macular degeneration, otherwise known as dry AMD? Anjali Shah, MD, ophthalmologist at Michigan Medicine, has answers.

Here are six things you and your family should know about treating the condition:

1. There's a new medication available for dry AMD

The medication is called pegcetacoplan, or Syfovre, and it was recently approved by the Food and Drug Administration. It has been shown to slow the progression of a severe form of dry AMD called geographic atrophy. It is not approved for other types of dry AMD.

It's important to note that the drug does not reverse or stop progression, but it may delay further vision loss. Based on clinical trials, we estimate that the drug slows the rate of progression by 1-3 months each year. In other words, if the disease was going to progress to a certain stage of severity in 24 months, it would take 27-30 months while on the drug.

2. There’s a specific way it needs to be given

This dry AMD medication needs to be injected into the eye between every 4 and 8 weeks, which requires a doctor's visit each time.

It's unclear how long patients need to be on the medication and  it's likely that the duration of treatment will be different for every person, but most people will need to continue treatment for several years. There are currently no drops or pills to treat dry AMD.

3. There are potential risks and possible side effects to the medicine

The clinical trials suggest that there's about a 10% risk of developing wet macular degeneration in the first year of treatment with Syfovre. Wet macular degeneration can be treated, but it would require different injections in the eye.

In addition, there are always risks to receiving injections of any type of medication in the eye. The biggest risk is getting an infection in the eye, which can cause permanent vision loss. This happens about 1 in every 3,000 injections.

4.  The medication is mostly recommended for a certain type of patient 

Though anyone with geographic atrophy can get the injection, it may only be an ideal treatment for a select group of patients. If the advanced dry AMD is threatening high-resolution central vision, it may have a benefit that increases over time. In the clinical trials, there was no improvement in vision in 1 to 2 years. You should talk to your doctor to find out if this treatment would be appropriate for you.

5. Experts say they haven't seen vision improvement from the medication

In the clinical trials, there was no improvement in vision in the first two years after starting treatment.  The studies suggest that there may be some visual benefit over time, but there is currently no data to confirm that.

6. A retina specialist should be consulted with 

If you have any questions about dry AMD or its treatment, it's best to contact a retina doctor. They can provide you with personalized information and advice.


More Articles About: Ophthalmologist Eye Care & Vision Preventative health and wellness retinal degeneration retinal repair Hospitals & Centers Pharmacy Kellogg Eye Center
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories hospital beds in hallway
Health Lab
Using data to drive sepsis care
Michigan Medicine expert, Hallie Prescott, M.D., discusses successful statewide efforts to improve sepsis treatment–and setting the bar for change at the national level
Mature forest on fire
Health Lab
Wildfires: How to protect your lung health in poor air quality
With raging wildfires affecting air quality, experts say protecting your lung health is key.
woman on left smiling and house on right painted white with greenery
Health Lab
Preserving an artist’s vision after diabetic retinal disease
Kim Hartman is an artist with Type 1 diabetes. She started developing vision problems and doctors at Michigan Medicine helped her slow the vision loss and manage it.
child looking at family outside of kitchen area
Health Lab
Encouraging spirituality in teens without forcing participation
Among parents who plan to attend religious services this holiday season, nearly half would insist their teen join even if they didn’t want to, a poll suggests.
friends adults thanksgiving dinner table
Health Lab
How to safely celebrate the holidays and avoid getting sick
This holiday season, follow these five expert-approved steps to celebrate safely and avoid getting sick.
prescription pad drawn
Health Lab
Reducing dose of popular blood thinners may limit risk of future bleeding
For people taking the popular blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.